Not provided
Not provided
Not provided
Not provided
Not provided
Institutional and funding constrains
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
metformin alleviates drug-induced osteoarthritis (OA)-like change in mice knee joint through activating autophagy and downregulating apoptosis. Metformin exerts its protective effects against OA through the AMPKa2/ SIRT1 pathway. Metformin suppresses IL-1β-induced oxidative and osteoarthritis-like inflammatory changes by enhancing the SIRT3/PINK1/Parkin signaling pathway, thereby indicating metformin's potential in prevention and treatment of osteoarthritic joint disease.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Metformin | Experimental | Metformin 1000 mg daily plus Celecoxib 200mg capsule |
|
| Placebo | Experimental | Placebo tablet daily plus Celecoxib 200mg capsule |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Metformin | Drug | Metformin 1000mg tablet plus celecoxib 200 mg capsule |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Visual Analogue scale assessment of pain | the change of Visual Analogue Scale (VAS) pain score from baseline to posttreatment | week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| WOMAC change | the change of WOMAC Osteoarthritis Index from baseline to posttreatment | week 12 |
| the change of Short Form 36 Questionnaire (SF-36) score from baseline to posttreatment | The SF-36 is a generic instrument to assess health-related quality of life. It consists of 36 questions and assesses 8 dimensions: physical functioning, role physical, pain index, general health, vitality, social functioning, role emotional, and mental health index. It also provides 2 summary measures of physical and mental components. The SF-36 score ranges from 0 to 100, with higher scores indicating better health status. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Those patients were excluded from the present study who:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculty of Pharmacy | Shibīn al Kawm | Menoufia | 13829 | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008687 | Metformin |
| ID | Term |
|---|---|
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Placebo tablet plus celecoxib 200 mg capsule |
|
| week 12 |
| Adverse drug reaction | Clinical side effects | 12 weeks |
| AMPK expression | AMPK gene expression | 12 weeks |
| Serum level Tumor necrosis factor- alpha (TNF-α) | Serum level Tumor necrosis factor- alpha (TNF-α) | 12 weeks |
| Serum levels of IL-1β | Serum levels of IL-1β | 12 weeks |
| IL-17 | Serum levels of IL-17 | 12 weeks |